Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5

Two hypomethylating agents (HMAs), azacitidine and decitabine, have demonstrated clinical activities in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); however, potential problems include development of acquired resistance. HMA-resistant patients have very poor prognosis and this co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hur, Eun-Hye, Jung, Seung-Hyun, Goo, Bon-Kwan, Moon, Juhyun, Choi, Yunsuk, Choi, Dae Ro, Chung, Yeun-Jun, Lee, Je-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355301/
https://www.ncbi.nlm.nih.gov/pubmed/28052028
http://dx.doi.org/10.18632/oncotarget.14342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355301/
https://www.ncbi.nlm.nih.gov/pubmed/28052028
http://dx.doi.org/10.18632/oncotarget.14342

Ejemplares similares